Is C4 Therapeutics (CCCC) One of the Best Biotech Penny Stocks to Buy According to Analysts?

Core Insights - C4 Therapeutics Inc. (NASDAQ:CCCC) is recognized as a promising biotech penny stock by analysts, with Barclays recently lowering its price target to $5 from $10 while maintaining an Overweight rating [1] - TD Cowen initiated coverage with a Buy rating, emphasizing the company's unique position in achieving clinical validation for both molecular glues and heterobifunctional degraders, particularly highlighting cemsigwat/Cemsi's potential in treating multiple myeloma [2] Company Developments - In Q3 2025, C4 Therapeutics' lead candidate, cemsidomide, demonstrated a 53% overall response rate at the highest dose level of 100 µg in Phase 1 trials for multiple myeloma, showcasing a differentiated safety profile in heavily pre-treated patients [3] - The company plans to launch the Phase 2 MOMENTUM trial in combination with dexamethasone in Q1 2026, with potential for accelerated approval, followed by a Phase 1b trial with Pfizer's elranatamab in Q2 2026 [4] - C4 Therapeutics is also utilizing its TORPEDO platform to advance a discovery pipeline targeting non-oncology indications, indicating a broader strategic focus beyond oncology [4]